Research programme: hypoxia inducible factor targeting therapies - Akebia Therapeutics

Drug Profile

Research programme: hypoxia inducible factor targeting therapies - Akebia Therapeutics

Alternative Names: AKB 5169; JNJ 5169

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Akebia Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action Hypoxia inducible factor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 28 Mar 2018 Akebia Therapeutics has issued and pending patents for AKB 5169 composition of matter, pharmaceutical compositions, and methods of treatment in USA and additional patents issued or pending in countries worldwide
  • 28 Mar 2018 Akebia Therapeutics announces intention to submit IND to the US FDA for Inflammatory bowel disease in 2018
  • 14 Feb 2017 Akebia Therapeutics enters into an agreement with Janssen Pharmaceutica to license hypoxia-inducible factor (HIF)-targeting product candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top